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INTRODUCTION 
              Intracranial hypertension is a common feature of many illness 
treated in PICU. The early signs and symptoms of intracranial 
hypertension tend to be nonspecific. The classic Cushings triad of 
bradycardia, hypertension, and apnea occurs late and often not manifest 
fully in children. 
             Most of our understandings and approach to treatment is based 
on studies of patients with traumatic brain injuries. Whether those 
concepts are directly relevant to the pathophysiologic processes 
involved in more global CNS injuries such as hypoxia, infection and 
metabolic disorders, remain a matter of debate. 
            Within constraints of a closed skull, an enlargement of brain 
tissue (cerebral edema), an increased volume of CSF, or an increased 
volume of blood or the presence of a space-occupying lesion (SOL) 
such as a tumour or an abscess will initially reduce the size of the other 
compartments and later increase intracranial pressure, once the 
compensatory mechanisms fail. 
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Cerebral edema 
             The brain occupies about 80% of the volume of the skull. Apart 
from solid tumours, increase in brain compartment is generally a result 
of cerebral edema. Cerebral edema is the most common cause for 
intracranial hypertension in children treated in PICU. 
Types of cerebral edema 
             Cerebral edema can be divided into three forms: vasogenic, 
hydrostatic, and cytotoxic. 
             Vasogenic edema occurs in areas of inflamed tissue 
characterized by increased capillary permeability, and is most typical 
around CNS tumours, abscesses, and infarcts. 
             Hydrostatic or interstitial edema is a result of elevated CSF 
hydrostatic pressures. It occurs primarily in lesions associated with 
obstruction to CSF flow, and in a typical periventricular distribution. 
           Cytotoxic edema is the most common of the three forms seen in 
the PICU and is, unfortunately, the least easily treated. It occurs as a 
result of direct injury to brain cells, often leading to irreversible cell 
swelling and death. This form of cerebral edema is typical of traumatic 
brain injuries, infections, hypoxic ischemic injuries and metabolic 
disease. 
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Aetiology 
          Cerebral edema is seen in the following neurological and non-
neurological conditions: 
Neurological conditions - 
a) Ischemic stroke and intracerebral haemorrhage 
b) Brain tumours 
c) Meningitis and encephalitis of all etiologies 
d) Other brain infections like cysticercosis, tuberculosis and 
toxoplasma. 
Non-neurological conditions - 
a) Diabetic ketoacidosis, lactic acidotic coma 
b) Malignant hypertension, hypertensive encephalopathy 
c) Fulminant viral hepatitis, hepatic encephalopathy, Reye’s 
syndrome 
d) Systemic poisoning (carbon monoxide and lead) 
e) Hyponatremia, SIADH 
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f) Opioid drug abuse and dependence 
g) Bites of certain reptiles and marine animals 
h) High altitude cerebral edema  
Clinical Features 
          A high index of suspicion is very important. The features of 
cerebral edema add on to and often complicate the clinical features of 
the primary underlying condition. Until the ICP reaches a level that 
produces local ischemia, cerebral edema per se will not produce clinical 
neurological abnormalities. 
Signs and symptoms [1] 
        Early – Poor feeding, vomiting, irritability, lethargy, seizures, 
hypertension 
       Late – GCS < 8, Coma, absent doll’s eye movement, decerebrate 
responses, cranial nerve palsies, abnormal respirations, bradycardia, 
hypertension, and apnoea 
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Investigations 
          Urgent imaging is indicated in afebrile coma and in the presence 
of focal signs or papilledema, as the diagnosis includes stroke, intra-
cranial bleed, tumour or hydrocephalus. However, any child who does 
not have a very obvious metabolic/ toxic cause for the coma generally 
requires to be imaged. 
          CT scan provides an excellent tool for in vivo determination of 
abnormalities in brain water content. The areas of edema appear as low 
density on unenhanced scan. This is due to the dilution of all the 
constituents of the white matter [2]. The anatomical specificity of CT 
permits detection of not only the presence but also the type of brain 
edema. This is helpful in differentiating nature of underlying lesion eg. 
infarction/tumour. However CT scan may be normal initially and it does 
not rule out raised ICP.  
          CT is also an excellent method for following the resolution of 
brain edema following therapeutic intervention. 
            An MRI may be more specific for early changes of herpes 
simplex encephalitis (where CT may be normal), posterior fossa and 
white matter pathology [1, 3]. 
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           Invasive ICP monitoring is an important tool to monitor cases 
where cerebral edema is present or anticipated. Unfortunately, the direct 
measurement of ICP and aggressive measures to counteract high 
pressures have not yielded uniformly beneficial results, and after two 
decades of popularity - the routine use of ICP monitoring remains 
controversial. The problem may be partly a matter of the timing of 
monitoring and the proper selection of patients for aggressive treatment 
of raised ICP. Whether ICP monitoring adds much to the management 
of these patients is still open to question. Clinical signs and imaging data 
on shift of brain tissue are probably more useful 
Treatment 
           Treatment of brain edema has not kept up with the advances in 
understanding of the mechanism producing the edema. 
General measures 
           When signs of elevated ICP are present certain measures for 
management should be initiated. 
Position of the patient - Elevation of head end of bed by 15-30 degrees 
to promote cerebral venous drainage is advisable and head is kept in 
midline to limit neck vein compression [4].  
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Correction of contributory factors - Correction of factors increasing 
ICP e.g. hypercarbia, hypoxia, hyperthermia, acidosis, hypotension and 
hypervolemia is helpful. Endotracheal intubation and mechanical 
ventilation to maintain PaCO2 in low 30s (controversial) [1, 3] may be 
helpful in impending herniation. 
Hypothermia - Multiple mechanisms for reduced brain temperature-
induced neuroprotection have been identified and include reduced 
metabolic rate and energy depletion, decreased excitatory transmitter 
release, reduced alterations in ion flux, reduced vascular permeability, 
edema and BBB disruption [5]. 
Fluid restriction - Fluid restriction minimally affects cerebral edema 
and, if pursued to excess, may result in episodes of hypotension, which 
may decrease cerebral perfusion pressure (mean arterial pressure – ICP) 
and is associated with worse neurologic outcome [6]. Fluid restriction is 
not warranted as a routine unless in specific situation like SIADH. 
Glucose containing solutions should be avoided; euvolemia should be 
maintained, 0.9%N or N/2 saline should be used; urinary losses should 
be replaced with 0.9%N saline in patients receiving mannitol; eventually 
to maintain mean arterial pressure [4]. 
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Medical treatment 
Osmotherapy 
            The most rapid and effective means of decreasing tissue water 
and brain bulk is osmotherapy [2]. Osmotic therapy is intended to draw 
water out of the brain by an osmotic gradient and to decrease blood 
viscosity. These changes would decrease ICP and increase cerebral 
blood flow (CBF). 
            Mannitol is the most popular osmotic agent. Mannitol has two 
distinct effects. The immediate effect is related to its rheological 
properties (decreased blood viscosity) resulting in a transient increased 
CBF followed by a more sustained fall in CBF [1]. The delayed osmotic 
effects occur after 15-30 minutes and last for 4-6 hours. IV Mannitol is 
given in the dosage of 0.25-0.5g/kg repeated 4-6 hourly. Mannitol 
should be avoided in case of hypotension, renal failure, serum 
osmolarity>320 mOsm/kg.  
            Hypertonic saline [HTS] is emerging as newer osmotherapy. 
Hypertonic saline can possibly affect the volume of the intracranial 
structures through various mechanisms. All or several of them are likely 
to be interacting to achieve the end result of hypertonic saline therapy: 
9 
 
reduction of cerebral edema and elevated ICP. These mechanisms [7] 
are summarised below:  
• HTS also acts like mannitol by establishing a constant 
osmolar gradient in order to draw fluid from the brain 
parenchyma but without the risks of dehydration and 
tubular damage as in the case of mannitol. Hence it may be 
of more benefit in conditions where mannitol should be 
avoided. 
• Reduced viscosity: Hypertonic saline enhances 
intravascular volume and reduces viscosity. The auto 
regulatory mechanisms of the brain vasculature have been 
shown to respond not only to changes in blood pressure but 
also to changes in viscosity. Thus, a decrease in blood 
viscosity results in vasoconstriction in order to maintain a 
stable cerebral blood flow. 
• Increased plasma tonicity: It has been postulated, based on 
experimental animal data that increased plasma tonicity, 
such as that seen after hypertonic saline administration, 
favours more rapid adsorption of CSF. 
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• Increased regional brain perfusion, possibly secondary to 
dehydration of cerebral endothelial cells and erythrocytes, 
facilitating flow through capillaries. 
• Increased cardiac output and mean arterial pressure, with 
resultant augmentation of cerebral perfusion pressure, most 
likely due to improvement of plasma volume and a positive 
inotropic effect. 
• Diminished inflammatory response to brain injury, which 
has been demonstrated with hypertonic saline 
administration. 
• Restoration of normal membrane potentials through 
normalization of intracellular sodium and chloride 
concentrations. 
        A variety of formulations of hypertonic saline solutions (2, 3, 7.5, 
10, and 23%) [8, 9] are used in clinical practice for the treatment of 
cerebral edema either as bolus or continuous infusions. The goal in 
using hypertonic saline is to increase serum sodium concentration to a 
range of 145 to 155 mEq/L (serum osmolality approximately 300–320 
mOsm/L) [10] 
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Corticosteroids 
           Corticosteroids lower intracranial pressure primarily in vasogenic 
edema because of their beneficial effect on the blood vessel. They have 
been less effective in cytotoxic edema [11]. 
Other agents 
            Barbiturates, procaine derivatives, indomethacin, propofol and 
THAM (Trihydroxy aminomethane) are some other agents which have 
been tried. Barbiturate coma is used in some centres in order to reduce 
the cerebral metabolic rate and thus the cerebral blood flow, although 
most references pertain to adults. 
Surgical treatment 
            Surgical treatment is occasionally recommended for large 
hemispherical infarcts with edema and life threatening brain-shifts. 
Temporary venticulostomy or craniotomy may prevent deterioration and 
may be lifesaving [12]. 
Conclusion 
            Though there has been good progress in understanding of 
pathophysiological mechanisms associated with cerebral edema, more 
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effective treatment is required and is still awaited. Certainly, the “ideal” 
agent for the treatment of cerebral edema - one that would selectively 
mobilize and / or prevent the formation of edema fluid with a rapid 
onset and prolonged duration of action, and with minimal side effects, 
remains to be discovered. 
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REVIEW OF LITERATURE 
            I] Yildizdas D, Altunbasak S conducted a retrospective study to 
evaluate the efficacy and side effects of hypertonic saline[HTS] and 
mannitol use in cerebral edema  in the Pediatric Intensive Care Unit 
Çukurova University, School of Medicine between June 2002 and May 
2004 [13]. Patients treated with mannitol, HTS, or both mannitol and HS 
were assigned as Group I, Group II, Group III respectively. Cerebral 
edema and increased intracranial pressure were identified based on the 
clinical and/or radiological (CT, MR) findings. Clinical findings 
included low consciousness level (GCS <8) plus one or more of the 
followings: Unequal, dilated or unreactive pupils, loss of brain stem 
reflexes (light and oculocephalic), cranial nerve palsies (III, VI) and 
Cushing's triad. In Group I, patients were treated with 0.5 g/kg mannitol 
for the first two doses and if needed the maintenance doses were 0.25 
g/kg/dose. In Group II, Hypertonic saline was given to provide a serum-
Na level of 155-165 mEq/L. Extra boluses were given depending on the 
serum Na level. Group III received both mannitol and hypertonic saline. 
In Group I – 22, Group II – 25, Group III – 20 were recruited. There was 
no statistically significant difference between groups in terms of age (P 
= 0.5), gender (P = 0.4), Glasgow coma scale and etiological causes (P = 
0.8). Mannitol was given for a total dose of 9.3 ± 5.0 (2-16) doses in 
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Group I, and 6.5 ± 2.8 (2-10) doses in Group III. Hypertonic saline was 
infused for 4-25 times in Group II. Although there was no statistically 
significant difference in the highest serum Na and osmolarity levels of 
the groups, duration of comatose state and mortality rate were 
significantly lower in Group II and Group III. Age, gender, cause of 
cerebral edema, electrolyte imbalance, hyperglycemia and 
hyperventilation had no significant impact on outcome. Limitations of 
this study: This was a retrospective study; Outcome variable of “duration 
of comatose state” included all patients irrespective of their survival 
status. Failure to sensor this time-to-event ‘duration of coma’ variable by 
mortality in this study could have been rectified. The p –value 0.003 
while comparing the outcome of mortality (proportion) appears to have 
error. Using the factual data about mortality and survival given by 
authors in this study, the calculated P value is 0.07.  
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II] Piyush Upadhyay and Tripathi conducted a prospective 
randomized study to compare the efficacy and side effects of 3% saline 
and mannitol in management of raised intracranial pressure in children 
at GSVM Medical College, Kanpur [14]. 200 Children aged 2 to 18 
months with clinical symptoms and signs of raised intracranial pressure 
were recruited. Patients with compromised renal function (increased 
serum creatine), hepatic encephalopathy, serum Na + (>150meq/l), 
diabetic ketoacidosis, cereberal malaria were excluded. Loading dose 
(5ml/kg) was followed by maintenance dose (2ml/kg) of mannitol or 3% 
hypertonic saline in corresponding groups for two days was 
administered. Comparison of average reduction of mean arterial 
pressure (pre and post drug) at definite time (6h) intervals was done to 
indirectly assess reduction in intracranial pressure. Decrease in MAP 
was found to be highly significant (p<0.001) at 0 hr in males 0, 6 hr in 
females and moderately significant at 12, 36 hr in females and 
significant (p<0.05) at 6, 24, 42 hr in males in 3% saline group. 
Decrease in coma hours was a highly significant finding (p<0.001) in 
3% saline group. No difference was noted in osmolality and mortality 
between both groups. Limitations of the study: Clinical criteria for 
raised intracranial pressure could have been clearly defined; mental 
status of the treated children could have been defined and considered for 
termination of treatment; side effects encountered during treatment 
could have been enumerated. 
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JUSTIFICATION 
           Cerebral edema is an important and frequent problem in 
neurocritically ill patient. This can result from various insults to the 
brain. Improving cerebral edema and decreasing ICP have been 
associated with improved outcome. However, all current treatment 
modalities are far from perfect and are associated with serious adverse 
events. Indiscriminate hyperventilation can lead to brain ischemia. 
Mannitol can cause intravascular volume depletion, renal insufficiency, 
and rebound ICP elevation; barbiturates are associated with 
cardiovascular and respiratory depression and prolonged coma; and 
cerebrospinal fluid drainage via intraventricular catheter insertion is 
highly invasive and may result in intracranial bleeding and infection. 
Other treatment modalities have been explored and hypertonic saline 
solution appears to be an appealing addition to the current therapeutic 
avenues for management of cerebral edema .Mannitol has been used 
extensively in treatment of cerebral edema in the past and is the time 
tested drug.  
                 In clinical situations there are instances where mannitol is 
contraindicated such as when the child is in shock or renal failure. 
Mannitol is well known to produce rebound effect, serum electrolyte 
disturbances and hypovolemia and this has led to continued search of 
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newer agents. Hence there is a need for the use of alternate drugs like 3% 
saline in managing cerebral edema. 3% saline has been regularly used in 
patients with intracranial injury, stroke, and DKA and has been found to 
be useful. However the role of 3% saline in other causes of cerebral 
edema has not been studied in pediatric population. A Retrosepective 
study done in Turkey [13] has revealed that 3% saline seems to be more 
effective than mannitol in cerebral edema. In our PICU, 3%saline is used 
as a treatment for raised ICP since 2004. This study was done to analyze 
the effects of hypertonic saline in children with cerebral edema and to 
compare this treatment modality with mannitol in terms of efficacy, side 
effects and outcome. 
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AIM 
              To study the effectiveness of 3% saline as an antiedema measure 
in children admitted with cerebral edema in the pediatric intensive care 
unit of a tertiary care children hospital in a developing country. 
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SUBJECTS AND METHODS 
STUDY DESIGN  :         Randomized Controlled Trial 
 
PLACE OF STUDY :       Pediatric Intensive Care Unit  
                                              Institute of Child Health and Hospital for  
                                              Children, Egmore, Chennai. 
PERIOD OF STUDY :        November 2008 to October 2010. 
STUDY POPULATION :     
            Children who are suspected to have cereberal edema between 3 
months to 12 years. 
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INCLUSION CRITERIA:  
            Children in the age group of 3 months to 12 years, with cerebral 
edema of any etiology who satisfy the criteria of diagnosis, admitted in 
the PICU were included. 
EXCLUSION CRITERIA: 
(i)  Children with cerebral edema but presenting with shock, renal 
failure or intracranial bleed on admission at PICU were excluded, 
as the hospital protocol in these children is to avoid mannitol. 
(ii)  Child presenting with afebrile status epilepticus, with or without 
previous history of seizures, who show clinical recovery in 6 – 8 
hours will not be included. 
(iii)  Children treated prior to PICU admission will be excluded. 
(iv)  Any of the features in criteria of diagnosis if explainable by other 
causes like neuroparalytic disorder (snake bite, GBS, drug 
poisoning) will be excluded. 
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CRITERIA OF DIAGNOSIS OF CEREBRAL EDEMA [15]: 
            Low GCS (<8) with any one of the following 
• persistent posturing after correction of shock and hypoxemia  
• Unequal, dilated or non-reacting pupil. 
• Cranial nerve palsies (3 and 6) 
• Bradycardia, Hypertension 
• Abnormal respiratory pattern 
• Papilledema 
• Radiological finding like effacement of the basal cisterns, 
thin, slit like or completely obliterated ventricles, obliterated 
cortical sulci, shift in midline and temporal lobe or 
cerebellar tonsillar herniation. 
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MANEUVER 
            80 children who satisfied the inclusion criteria were recruited 
during the study period. Two groups A and B were chosen. 40 children 
were assigned in each group with computer generated random number. 
The diagnosis of cerebral edema was made as per diagnostic criteria 
mentioned above. The study was approved by institutional ethical 
committee. Informed written consent was obtained from parents or 
caregivers. 
            In group A, children were treated with 20% mannitol. In group B, 
children were treated with 3% saline. The treatment otherwise were 
identical as per the PICU protocol in both groups. 20%mannitol was 
given at a dose of 1.5ml/kg IV, over 20 minutes, every 8 hourly [16, 17]. 
3%saline was given in a dose of 5ml/kg IV, over 20 minutes, every 8 
hourly [16, 17]. Serum sodium was targeted to maintain between 145-
155 meq/dl. Treatment for cerebral edema was terminated at a GCS score 
> 8 and absence of other signs of cerebral edema as mentioned in 
inclusion criteria. Maximum duration of treatment of cerebral edema was 
72 hours. Treatment was not continued if child developed complications 
necessitating termination of therapy. 
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            The outcome was analyzed in terms of survival/death, duration of 
coma and complication. Other parameters included were symptoms, 
clinical signs, fundus examination, duration of ventilation, CT finding 
and lab investigations. Complications recorded were hypernatremia, 
coagulopathy, pulmonary edema, subarachnoid hemorrhage, hemolysis, 
renal failure. Probable cause of cerebral edema such as  CNS infection, 
DKA, hepatic encephalopathy, infarct and tumors was arrived using the 
clinical criteria and lab investigations. Etiologies were grouped into 
infective, metabolic and others. Both group A and B were sub analyzed 
in terms of outcome with respect to age and etiological causes. 
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STATISTICAL ANALYSIS 
Data were analyzed with SPSS 14.0. Chi square and t test were 
used for independent samples; ANOVA test was used for continuous 
variables. Brock chart was used where ever necessary.   
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PROFILE OF CEREBRAL EDEMA 
Total cases recruited 80 100% 
Total cases recruited in Mannitol 
group 
40 50% 
Total cases recruited in 3%Saline 
group 
40 50% 
Total cases completed the study in 
Mannitol group 
35 43.7% 
Total cases completed the study in 
3%Saline group 
32 40% 
Cases not completed the study 13 16.3% 
Cases not completed the study include the children who died 
before improvement of cerebral edema and within 72 hrs (n-10); and 
those who were switched from mannitol to 3% saline due to fluid 
refractory shock (n-3) which developed during mannitol therapy.  
  
 
 
26 
 
 
 
AGE OF PRESENTATION 
 Mannitol 3%Saline p - value 
Mean (months) 59.17 46.47 
0.114 SD ± 42.00 ± 36.68 
Range 4 - 140 3 - 140 
• Age was comparable between both groups. 
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                                       GENDER DISTRIBUTION             
 
 Mannitol 3% Saline p - value 
Male 22 26 
0.49 Female 18 14 
Total 40 40 
 
• Gender distribution was comparable in both groups. ( p – value 
– 0.49) 
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ETIOLOGICAL DISTRIBUTION 
 
• Predominant cause for cerebral edema in both groups was 
infection. 62% in mannitol group and 60% in 3%saline group. 
• Metabolic causes include diabetic ketoacidosis, hepatic 
encephalopathy and suspected inborn error of metabolism. Other 
causes include SOL, infarct etc 
Cause Mannitol 3%Saline p - value 
Infective 25 24 
0.75 
Metabolic 12 11 
Others 3 5 
Total 40 40 
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• Symptoms were comparable between both groups.
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GLASGOW COMA SCALE 
 
• Glasgow coma scale ranged between 3-8 in mannitol group and 4-
8 in 3%saline group. GCS was comparable in both groups.                     
(p – value – 0.057). 
• In intubated children, GCS grimace score were used.  
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• Clinical signs were comparable between both groups. [Abst DEM – Absent dolls eye movement; 3N Pal – 3rd nerve 
palsy; 6N Pal – 6th nerve palsy] 
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DURATION OF COMA 
      
 
No. of cases 
completed 
therapy 
Mean 
(hrs) 
Standard 
deviation 
Range 
(hrs) 
Mannitol 35 59.89 29.67 13 - 146 
3%Saline 32 78.91 50.84 28 - 260 
  P – value   0.063 
• Duration of coma was compared only for those who completed 
the therapy.  
• Duration of coma was ranged between 13-146 hrs in mannitol 
group and 28-260 hrs in Saline group. 
• Even though the duration of coma seems to be more in 3%saline 
group, there was no statistical significance. 
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AGE COMPARISION OF DURATION OF COMA 
Age 
(mon) 
Group N 
Mean 
(hrs) 
Std. 
Deviation 
p - value 
<12 
Mannitol 4 67.25 41.70 
0.35 
3%Saline 7 50.71 15.41 
13-60 
Mannitol 16 63.12 33.60 
0.18 
3%Saline 16 84.43 52.66 
>60 
Mannitol 15 65.06 37.49 
0.20 
3%Saline 9 91.00 60.97 
 
•  Duration of coma in different age groups was not statistically 
significant between mannitol and 3%saline. 
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ETIOLOGICAL COMPARISION OF DURATION OF COMA 
Cause Group N 
Mean 
(hrs) 
Std. 
Deviation 
p - value 
Infective 
Mannitol 23 67.30 67.25 
0.35 
3%Saline 20 87.20 50.71 
Metabolic 
Mannitol 9 56.77 63.12 
0.18 
Saline 8 64.87 84.43 
Others 
Mannitol 3 65.33 65.06 
0.20 
3%Saline 4 65.50 91.00 
 
• Duration of coma in different etiological groups was not 
statistically significant between mannitol and 3%saline. 
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                                     OVERALL MORTALITY 
Outcome 
Mannitol 3%Saline Total 
No % No % No % 
Survived 
Died 
25 62.5% 16 40.0% 41 51.2%
15 37.5% 24 60.0% 39 48.8%
 p-value – 0.07 
• 62.5% survived in mannitol group. 40% survived in 3%saline 
group. 
• Mortality between the groups was not statistically significant. (p - 
0.07)  
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AGE COMPARISION OF MORTALITY 
Age (months) Mannitol 3%saline p - value 
≤ 12 4 (10%) 4 (10%) 0.29 
13 - 60 7(17.5%) 14 (35%) 0.058 
≥ 60 4(10%) 6 (15%) 0.06 
• Age wise comparisons of mortality were not statistically 
significant between the two groups.  
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ETIOLOGICAL COMPARISION OF MORTALITY 
Cause 
Mannitol 3%saline p - 
value Count % Count % 
Infective 
Survived 15 60.0% 10 41.7% 
.258 
Died 10 40.0% 14 58.3% 
Metabolic 
Survived 8 66.7% 3 27.3% 
.100 
Died 4 33.3% 8 72.7% 
Others 
Survived 2 66.7% 3 60.0% 
1.000 
Died 1 33.3% 2 40.0% 
• In different etiological groups, mortality was not statistically 
significant between the two groups. 
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• Dehydration and shock were significantly higher in mannitol group. 
• Hypernatremia was significantly higher in 3%saline group. 
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SERUM SODIUM VALUE 
           Minimum sodium value                      Maximum sodium value 
• Serum sodium at the time of recruitment into the study was 
comparable between the groups: 128 – 135meq/dl in mannitol 
group and 129 – 134 meq/dl in 3%saline group. 
• Maximum and minimum serum sodium value attained during the 
study were significantly higher in 3%saline group (p – 0.00) 
• 6 cases in 3%saline group had serum sodium levels > 155meq/dl 
during the therapy, hence subsequent doses was skipped until the 
serum sodium levels decreased to 155meq/dl. 
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DURATION OF VENTILATION  
 
Total ventilation
(hrs) 
Manual
(hrs) 
Mechanical 
(hrs) 
Mannitol 
Mean 136.88 11.37 127.90 
Range 0 - 648 0 - 103 0 - 648 
Std. Dev 155.19 19.72 152.02 
3%Saline 
Mean 280.45 15.95 264.00 
Range 0 – 3336* 0 -  236 0 -  3100 
Std. Dev 571.35 37.85 540.38 
Total 
Mean 208.66 13.66 195.95 
Range 0 -  3336* 0 -  236 0 -  3100 
Std. Dev 422.21 30.07 400.32 
p - value 0.06 0.35 0.06 
• Mean ventilation duration was 136 hrs in mannitol group (0-
648hrs) and 280 hrs in saline group (0-3336hrs). Ventilation 
duration was not statistically significant between both groups. 
∗ In 3%saline group, one child with TBM was ventilated for 
3336hrs (4 ½ months) and this child recovered with neurological 
sequelae. 
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OTHER OBSERVATIONS 
• CT Brain was taken in 80% of mannitol group and in 72.5% of 
3%saline group. 
• 52.5% of both groups had features of cerebral edema in CT brain.  
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                                             DISCUSSION 
             The earliest description in the literature of the use of osmotic 
agents dates back to 1919 [18]. While studying the transport of salt 
solutions into the neuraxis, Weed and McKibben observed that 
intravenous administration of a concentrated salt solution resulted in an 
inability to withdraw CSF from the lumbar cistern due to a collapse of 
the thecal sac. This serendipitous observation was followed by an 
elegant set of experiments in an animal model in which they 
demonstrated (under direct visualization via a craniotomy) regression of 
the brain away from the cranial vault with intravenous infusion of 
hypertonic saline solutions and herniation of brain tissue with 
administration of hypotonic fluids. This set of observations has formed 
the basis for osmotherapy. Concentrated urea was the first agent to be 
used clinically as an osmotic agent. [8,9,19]. Its use was short-lived and 
is of historic interest only because of several untoward side effects 
(nausea, vomiting, diarrhea, and coagulopathy) [19]. The interest in 
elevating plasma oncotic pressure as a strategy to ameliorate cerebral 
edema with the use of concentrated human plasma proteins, which 
appeared briefly in 1940, was short-lived due to several concerns, 
including cost, short half-life, cardiopulmonary effects, and allergic 
reactions [19]. Glycerol was possibly the second osmotic agent to be 
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used clinically. Mannitol, an alcohol derivative of simple sugar 
mannose, was introduced in 1960 and has since remained the major 
osmotic agent of choice in clinical practice [8,9,19]. Its long duration of 
action (4–6 hours) and relative stability in solution have enhanced its use 
over the years. The extra osmotic properties of mannitol have been 
studied extensively and may provide additional beneficial effects in 
brain injury, including decreases in blood viscosity, resulting in 
increases in rCBF and CPP, and a resultant cerebral vasoconstriction 
leading to decreased CBV,[20,21] free radical scavenging,[22] and 
inhibition of apoptosis [23]. 
            Renewed interest in hypertonic saline solutions reappeared in the 
1980s, when they were used in small-volume resuscitation in patients 
experiencing hemorrhagic shock. [8,9]. These studies demonstrated that 
prehospital restoration of intravascular volume improved morbidity and 
mortality rates and physiological parameters (such as systemic blood 
pressure, cardiac index, and tissue perfusion) in this subset of patients 
[24]. In subsequent studies, cerebral effects of these solutions were 
investigated in well-controlled experimental studies in animal models of 
acute brain injury. Like mannitol, hypertonic saline also possesses 
unique extraosmotic properties, including modulation of CSF production 
and resorption and accentuation of tissue oxygen delivery [8,9]. 
44 
 
             The use of hypertonic saline solution in the treatment of cerebral 
edema and elevated ICP in the clinical setting is largely based on an 
extension of laboratory-based research, a few prospective studies in 
humans, and anecdotal case reports. The first report to demonstrate the 
efficacy of hypertonic saline in patients with TBI [25] involved two 
patients with elevated ICP refractory to mannitol who were treated 
successfully with a single intravenous bolus of 30% saline, after which 
ICP decreased and systemic perfusion improved. Continuous 
intravenous infusion of 2.5 and 5.4% hypertonic saline enhanced CPP 
and improved somatosensory evoked potentials after brainstem trauma 
[26]. Likewise, in an uncontrolled, nonrandomized study, [27] 
reductions in ICP were noted with the use of 7.5% hypertonic saline 
treatment following TBI. 
          Few studies have made direct comparisons between mannitol and 
hypertonic saline. In a prospective, randomized comparison of 2.5 ml/kg 
of either 20% mannitol (1400 mOsm/kg) or 7.5% hypertonic saline 
(2560 mOsm/ kg) in patients undergoing elective supratentorial 
procedures,[28] ICP and intraoperative clinical assessment of brain 
swelling were similar in both treatment groups. 
              Most of these study perspectives were from adult population 
and only few studies were available in pediatric population. In a double-
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blind crossover study, in which 3% hypertonic saline for TBI was used 
in a pediatric population, ICP was reduced by approximately 5 mmHg 
for 2 hours compared with ICP in patients who required equal volumes 
of isotonic saline. These available studies have compared population 
with traumatic etiology which contribute meagrely to cerebral edema in 
pediatric patients. Only two studies done by Yildizdas., et al and Piyush 
Upathyay., et al were based on non traumatic etiology in pediatric 
populations.  
           Our study is a prospective analysis done in children between ages 
of 3 – 140 months. This was comparable with the study done by 
Yildizdas et al., (1-120mon) whereas in study by Upadhyay., et al 
included adolescent population. In our study etiological factors included 
infective, metabolic, infarct and space occupying lesion. This was 
comparable with other two studies. 
          In our study, male population (55-65%) were predominant similar 
to Upadhyay et al. In the study by Yildizdas et al, female population (52-
60%) was predominant. Clinical signs and symptoms in our study were 
comparable with other studies. 
         In our study, Glasgow coma scale in the both groups was 
6.77±1.352 (3-8) and 6.04±1.51 (4-8). This was higher compared to 
Yildizdas et al. This was probably because in our study, we recruited 
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cases without shock. Cases with low GCS tend to have shock and would 
not have been recruited into the study. 
        The duration of coma in our study was 59.89±29.67 (mannitol) and 
78.91±50.84 (3%saline).This was of shorter duration when compared to 
study by Yizdizdas et al (123±48.2; 88.6±42.5; 87.5±26.1). In our study, 
even though duration was higher in 3%saline group, this did not attain 
statistical significance.  
      In our study, overall mortality, age wise mortality and etiological 
mortality comparisons were not statistically significant similar to the 
study by Upadhyay et al. whereas study by Yildizdas et al showed 
statistically decreased mortality in hypertonic saline group.  
          In terms of the efficacy and side effect profile of the saline 
treatment in cerebral edema, the optimum serum-Na concentration and 
osmolarity are still debatable. It was postulated to maintain the serum 
sodium between 145 – 155meq/dl (serum osmolality approximately 300-
320 mosm/L). In our study, serum sodium was maintained between 132-
137meq/dl in mannitol and 145-157meq/dl in 3%saline group which was 
similar to the study by Upadhyay et al. (123-130; 122-153 meq/dl).  
        Complications like dehydration, shock were significantly more in 
mannitol group and in 3%saline group, hypernatremia was significantly 
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higher. These complications were similar to other studies [13,14]. There 
was no significant tendency for hemolysis or haemorrhage observed in 
study. 
       The disadvantage in our study is the fact that ICP monitoring was 
not conducted. However clinical efficacy has been compared between 
two groups by mortality assessment and duration of coma. 
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SUMMARY 
In this prospective randomized control study done at the pediatric 
intensive care unit, Institute of child health, Chennai, 40 patients each 
were recruited in both mannitol and 3%saline group for treatment of 
cerebral edema. The following are the highlights of the study: 
a) Age group was between 3 -140 months. 
b) Gender distribution showed slight male preponderance. 
c)  Etiology was similar in both groups; infection being the 
predominant underlying cause. 
d) GCS was similar in both groups. 
e) Clinical signs and symptoms were comparable between both 
groups. 
f) Duration of coma didn’t reveal statistically significant difference 
between the groups. 
g) Overall mortality, age wise and etiology wise mortality were 
similar between the groups. 
h) Shock and dehydration was significantly more in mannitol group  
i) Hypernatremia was significantly higher in 3%saline group. 
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CONCLUSION 
To conclude, in the treatment of cerebral edema of infectious, 
metabolic and non traumatic origin in children, 3%saline is as effective 
and safe as mannitol.  
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RECOMMENDATION 
3% saline being as effective and safe as mannitol, we need further 
research on the following issues related to 3%saline in the treatment of 
cerebral edema: 
¾ The target serum sodium value. 
¾ The duration of treatment of 3%saline. 
¾ The preferable mode of administration, either 3%saline 
bolus or continuous infusion. 
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GCS                –   Glasgow coma scale 
HTS                –   Hypertonic saline 
SPSS               –   Statistical Package For Social Sciences 
DKA               –   Diabetic Ketoacidosis 
CT                   –   Computerised Tomography 
THAM            –   Trihydroxy amminomethane 
CBF                –   Cerebral Blood Flow 
ICP                 –   Intracranial pressure 
MRI                –   Magnetic Resonance Imaging 
CSF                –   Cerebrospinal fluid 
PICU              –   Pediatric Intensive Care Unit 
TBI                 –   Traumatic Brain Injury 
CPP                -          Cerebral Perfusion Pressure 
CBV               -           Cerebral Blood Volume 
DEM              -           Dolls Eye Movement 
SIADH           –   Syndrome of inappropriate antidiuretic  
    hormone secretions 
BIBLIOGRAPHY 
1) Larsen GY, Vernon DD, Dean JM. Evaluation of the Comatose 
Child. In: Rogers MC, ed. Textbook of Pediatric Intensive Care. 
3rd edn. Baltimore: Williams and Wilkins; 1996;735-745 
2) Pollay M. Blood-Brain Barrier, Cerebral Edema. In: Wilkins RH, 
Rengachary SS, editors. Neurosurgery. 2nd ed. New York Mc 
Graw Hill Book Co., 1996; 335-44. 
3) Kirkham FJ. Non-traumatic coma in children. Arch Dis Child 
2001; 85: 303-31 
4) Biller J, Bruno A. Acute ischaemic stroke. In: Johnson RT,Griffin   
JW, editors. Current Therapy In Neurologic Disease: 5th ed. St 
Louis: Mosby, 1997; 191-7.
5) Barone FC, Feuerstein GZ, White RF. Brain cooling during 
transient focal ischemia provides complete neuroprotection. 
Neurosci Biobehav Rev 1997; 21(1):31-44. 
6) 19Zornow MH, Prough DS. Fluid management in patients with 
traumatic brain injury. New Horiz 1995; 3:488-98. 
7) Alexandros L. Georgiadis and Josè I. Suarez.Hypertonic saline 
for cerebral edema. Current Neurology and Neuroscience reports
Volume 3, Number 6, 524-530, DOI: 10.1007/s11910-003-0058-1 
8) Bhardwaj A, Ulatowski JA: Cerebral edema: hypertonic saline 
solutions. Curr Treat Options Neurol:1999, 1: 179–188 
9) Bhardwaj A, Ulatowski JA: Hypertonic saline solutions in brain 
injury. Curr Opin Crit Care: 2004; 10:126–131  
10) Rogers’ Textbook of pediatric intensive care 4th ed. Pierre 
Tissieres, Denis J.Devictor. Chap-88;1541-1543 
11) Rosenberg GA. Brain edema and disorders of cerebrospinal fluid 
circulation. In: Bradley WG, Daroff RB, Ferichel GM, Marsden 
CD, editors. Neurology in clinical practice. Vol 2.3rd ed. Boston: 
Butterworth Heinmann 2000; 2:1545-59. 
12) Koh MS, Goh KY, Tung MY, Chan C. Is decompressive 
craniectomy for acute cerebral infarction of any benefit? Surg 
Neurol 2000; 53(3):225-30. 
13) Indian Pediatrics. Hypertonic Saline Treatment in Children with 
Cerebral Edema. Yildizdas D, Altunbasak S, Celik U; Vol 53 
14) Journal of pediatric neuroscience. Piyush Upadhyay, 
V.N.Tripathi, R.P.Singh; 2010/Jan-Jun/Vol 5 
15) Stack C. Trauma. In: Stack C, Dobbs P eds.Essentials of Pediatric 
Intensive Care, 1st edn.London: Greenwich Medical Media 
Limited, 2004: 155-161.
16) http://www.ispad.org/FileCenter/10Wolfsdorf_Ped_Diab_2007,8.
22-43.pdf 
17) Chapter 4, Evidence-based Paediatric and Adolescent Diabetes, 
Eds Allgrove, Swift & Greene, Blackwell Publishing, ISBN 978-
1-4051-5292-1 
18) Weed LH, McKibben PS: Experimental alteration of brain bulk. 
Am J Physiol:1919; 48:531–555 
19) Paczynski RP: Osmotherapy. Basic concepts and controversies. 
Crit Care Clin:1997; 13:105–129 
20) Rosner MJ, Coley I: Cerebral perfusion pressure: a hemodynamic 
mechanism of mannitol and the postmannitol hemogram. 
Neurosurgery:1987; 21:147–156 
21) Schrot RJ, Muizelaar JP: Mannitol in acute traumatic brain injury. 
Lancet:2002; 359:1633–1634 
22) Alvarez B, Ferrer-Sueta G, Radi R: Slowing of peroxynitrite 
decomposition in the presence of mannitol and ethanol. Free 
Radic Biol Med:1998, 24:1331–1337  
23) Korenkov AI, Pahnke J, Frei K, Warzok R, Schroeder HW, Frick 
R, et al: Treatment with nimodipine or mannitol reduces 
programmed cell death and infarct size following focal cerebral 
ischemia. Neurosurg Rev:2000; 23:145–150  
24) Zornow MH: Hypertonic saline as a safe and efficacious 
treatment of intracranial hypertension. J Neurosurg Anesth: 1996; 
8:175–177
25) Worthley LI, Cooper DJ, Jones N: Treatment of resistant 
intracranial hypertension with hypertonic saline. Report of two 
cases. J Neurosurg:1988; 68:478–481  
26) Gemma M, Cozzi S, Poccoli C, Magrin S, De Vitis A, Cenzato 
M: Hypertonic saline fluid therapy following brain stem trauma. J 
Neurosurg Anesthesiol:1996; 8:137–141  
27) Weinstabl C, Mayer N, Germann P, Steltzer P, Hammerle AF: Hy 
pertonic, hyperoncotic hydroxy ethyl starch decreases in 
tracranial pressure following neurotrauma. Anesthesiology: 1992; 
75:A201 (Abstract) 
28) Gemma M, Cozzi S, Tommasino C, Mungo M, Calvi MR, 
Capriani A, et al: 7.5% hypertonic saline versus 20% mannitol 
during elective neurosurgical supratentorial procedures. J 
Neurosurg Anesth:1997; 9:329–334  
ABBREVIATIONS
GCS  –   Glasgow coma scale 
HTS        – Hypertonic saline 
SPSS               –   Statistical Package For Social Sciences 
DKA       –   Diabetic Ketoacidosis 
CT         – Computerised Tomography 
THAM            –   Trihydroxy amminomethane 
CBF                – Cerebral Blood Flow 
ICP                 – Intracranial pressure 
MRI                –   Magnetic Resonance Imaging 
CSF                –   Cerebrospinal fluid 
PICU       – Pediatric Intensive Care Unit 
TBI                 – Traumatic Brain Injury 
CPP                - Cerebral Perfusion Pressure 
CBV   - Cerebral Blood Volume 
DEM              -           Dolls Eye Movement 
SIADH           – Syndrome of inappropriate antidiuretic  
    hormone secretions
